Devyser Diagnostics AB (publ) (STO:DVYSR)
62.20
-0.10 (-0.16%)
Jul 24, 2026, 5:29 PM CET
Devyser Diagnostics AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 81 | 77.5 | 144.5 | 262.9 | 363.6 | 377.64 |
Cash & Short-Term Investments | 81 | 77.5 | 144.5 | 262.9 | 363.6 | 377.64 |
Cash Growth | -19.32% | -46.37% | -45.04% | -27.69% | -3.72% | 4426.40% |
Accounts Receivable | 60.1 | 56.8 | 50.9 | 33.7 | 27.5 | 18.6 |
Other Receivables | 1.2 | 3 | 10.7 | 9.7 | 4.8 | 7.04 |
Total Trade Receivables | 61.3 | 59.8 | 61.6 | 43.4 | 32.3 | 25.64 |
Inventory | 44.4 | 37 | 30.2 | 20.6 | 10.1 | 6.73 |
Other Current Assets | 19.3 | 29.9 | 15.9 | 14.9 | 6 | 2.65 |
Total Current Assets | 206 | 204.3 | 252.3 | 341.8 | 412.1 | 412.66 |
Net Property, Plant & Equipment | 74.9 | 82.9 | 97.5 | 91.6 | 30.5 | 16.69 |
Other Intangible Assets | 176.2 | 153.9 | 95 | 49.3 | 32.9 | 18.01 |
Goodwill | 15.2 | 6.6 | 7 | 6.7 | 6.8 | 0.24 |
Long-Term Investments | - | - | - | - | - | 2.06 |
Other Long-Term Assets | 20.7 | 22.1 | 22 | 20.7 | 18.4 | 7.21 |
Total Assets | 493.1 | 469.7 | 473.8 | 510.1 | 500.6 | 456.87 |
Accounts Payable | 18.1 | 17.9 | 12.6 | 14.2 | 9.6 | 9.66 |
Accrued Expenses | 25.5 | 22.5 | 25.8 | 20 | 20.6 | 12.88 |
Current Portion of Long-Term Debt | - | - | 0.1 | - | 0.1 | - |
Current Portion of Leases | 13.2 | 14.1 | 13.6 | 17.5 | 5.4 | 3 |
Other Current Liabilities | 13.7 | 16.4 | 20.5 | 11.2 | 15.6 | 3.88 |
Total Current Liabilities | 70.6 | 70.9 | 72.6 | 62.9 | 51.2 | 29.43 |
Long-Term Debt | 0.2 | 0.3 | 0.3 | 0.6 | 0.6 | - |
Long-Term Leases | 32.4 | 37.5 | 45.1 | 56.7 | 15.1 | 9.96 |
Other Long-Term Liabilities | 9 | 6.7 | 6.7 | 4.9 | 2.3 | 0.8 |
Total Long-Term Liabilities | 41.6 | 44.4 | 52.1 | 62.1 | 18 | 10.76 |
Total Liabilities | 112.2 | 115.3 | 124.7 | 125 | 69.2 | 40.18 |
Common Stock | 1 | 1 | 1 | 0.9 | 0.9 | 0.87 |
Additional Paid-in Capital | 567.6 | 545.7 | 536.5 | 513.2 | 507.6 | 449.28 |
Accumulated Other Comprehensive Income | 2.1 | 2.6 | 0.6 | 1.2 | 0.8 | -0.44 |
Retained Earnings | -189.7 | -194.9 | -189 | -130.2 | -77.9 | -33.03 |
Shareholders' Equity | 381 | 354.3 | 349 | 385.1 | 431.4 | 416.68 |
Total Liabilities & Equity | 493.1 | 469.7 | 473.8 | 510.1 | 500.6 | 456.87 |
Total Debt | 45.8 | 51.9 | 59.1 | 74.8 | 21.2 | 12.96 |
Net Cash (Debt) | 35.2 | 25.6 | 85.4 | 188.1 | 342.4 | 364.68 |
Net Cash Growth | -23.81% | -70.02% | -54.60% | -45.06% | -6.11% | - |
Net Cash Per Share | 2.11 | 1.54 | 5.19 | 11.03 | 20.49 | 30.53 |
Book Value | 381 | 354.3 | 349 | 385.1 | 431.4 | 416.68 |
Book Value Per Share | 22.84 | 21.26 | 21.22 | 22.58 | 25.82 | 34.88 |
Tangible Book Value | 189.6 | 193.8 | 247 | 329.1 | 391.7 | 398.43 |
Tangible Book Value Per Share | 11.36 | 11.63 | 15.02 | 19.30 | 23.44 | 33.35 |